

Not for release to US wire services or distribution in the United States

12 June 2024

Dear Shareholder

NOTICE TO ELIGIBLE SHAREHOLDERS OF ACCELERATED NON-RENOUNCEABLE ENTITLEMENT OFFER

On 4 June 2024, Genetic Signatures Limited (**Genetic Signatures** or the **Company**) announced that it is undertaking a capital raising of up to approximately \$30 million (before costs) through the issue of new fully paid ordinary shares at an offer price of \$0.75 per share (**New Shares**), comprising:

- (a) a placement of New Shares to sophisticated and professional investors to raise up to approximately \$6 million (before costs); and
- (b) a fully underwritten pro rata accelerated non-renounceable entitlement offer to raise approximately \$24 million (before costs), whereby eligible shareholders will be invited to subscribe for 1 New Share for every 5.82 existing shares held on the record date (**Entitlement Offer**).

The Entitlement Offer is being made without a prospectus or product disclosure document in accordance with section 708AA of the *Corporations Act 2001* (Cth) (**Corporations Act**) as modified by the *Australian Securities and Investments Commission (ASIC) Legislative Instrument (Non-Traditional Rights Issues) 2016/84*.

The Entitlement Offer comprises an offer to eligible institutional shareholders (**Institutional Entitlement Offer**) and an offer to Eligible Retail Shareholders (as defined below) (**Retail Entitlement Offer**) to participate on the same terms.

The Institutional Entitlement Offer has already closed and the results have been announced to the ASX.

The Company has today lodged a retail entitlement offer booklet with the ASX (available to view on the ASX website at <https://www.asx.com.au/markets/company/gss> and the Company's website <https://geneticsignatures.com/investors> which sets out further details in respect of the Retail Entitlement Offer (**Retail Offer Booklet**).

Eligibility criteria

The Company has determined, pursuant to ASX Listing Rule 7.7.1(a) and section 9A of the Corporations Act, that it would be unreasonable to make offers to shareholders in all countries outside Australia and New Zealand in connection with the Retail Entitlement Offer. This is due to the legal and regulatory requirements in countries other than Australia and New Zealand and the potential costs to the Company of complying with these requirements, compared with the relatively small number of shareholders in those countries, the relatively small number of existing shares they hold and the relatively low value of new shares to which those shareholders would otherwise be entitled to subscribe for.

Shareholders who are eligible to participate in the Retail Entitlement Offer are shareholders who:

- are registered as the holder of existing shares as at 7.00pm (Sydney time) on Thursday, 6 June 2024 (Record Date);
- have a registered address on the Company's share register that is in Australia or New Zealand; and
- were not invited to participate in the Institutional Entitlement Offer or treated as an ineligible institutional shareholder for that purpose.

How to access the Entitlement Offer

Genetic Signatures will not be printing and dispatching hard copies of the Retail Offer Booklet. Instead, Shareholders who are eligible to participate in the Retail Entitlement Offer (**Eligible Retail Shareholders**) that have elected to receive notices by email will receive an email with details of how to access the Retail Offer Booklet and personalised Entitlement and Acceptance Form. Eligible Retail Shareholders receiving their documents by post will receive a letter with details of how to access the Retail Offer Booklet and personalised Entitlement and Acceptance Form.

An electronic copy of the Retail Offer Booklet and your Entitlement and Acceptance Form is also available and accessible by you (using your Securityholder Reference Number (SRN) or Holder Identification Number (HIN) from your latest Holding Statement, and your postcode) at the following link: www.investorserve.com.au.

Eligible Retail Shareholders in Australia and New Zealand can also obtain a copy of the Retail Offer Booklet (free of charge) during the Retail Entitlement Offer period from the Company's website at <https://geneticsignatures.com/au/investors/announcements/> or by calling the Share Registry on 1300 737 760 (from within Australia) or +61 2 9290 9600 (from outside of Australia) from 9.00am to 5.00pm (Sydney time), Monday to Friday.

To apply under the Entitlement Offer using these paper copy documents, you will still need to make payment via BPay®. For New Zealand shareholders please follow the instructions on your Entitlement and Acceptance Form and payment instruction form to make payment via Electronic Funds Transfer (EFT).

Key features of the Retail Entitlement Offer

The Entitlement Offer is available to Eligible Retail Shareholders.

The Entitlement Offer is non-renounceable, meaning that Eligible Shareholders will not be able to transfer their Entitlements pursuant to the Entitlement Offer and, if they do not take up their Entitlements pursuant to the Entitlement Offer, their holdings will be diluted.

The Entitlement Offer is lead managed and fully underwritten by Bell Potter Securities Limited and Taylor Collison Limited as joint lead managers and underwriters.

All of the Shares issued pursuant to the Entitlement Offer will rank equally with the existing Shares on issue in the Company from the date of allotment.

Actions required by eligible retail shareholders

Your entitlement is shown on the personalised Entitlement and Acceptance Form that accompanies the Retail Offer Booklet (which is accessible as set out above). The choices

available to eligible retail shareholders are described in the Retail Offer Booklet. In summary, eligible retail shareholders may:

- take up their Entitlement in full;
- take up part of their Entitlement and allow the balance to lapse; or
- do nothing, in which case their Entitlement will lapse.

Further details of how to submit an application is provided in the Retail Offer Booklet.

Authorised for release by the board of directors.

For more information, please contact:

Mr Karl Pechmann
Company Secretary
Genetic Signatures Limited
Email: investor@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures' proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its EasyScreen™ respiratory kits and the growing interest in its gastroenteritis products to further commercialise its **3base®** technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.

Not an offer in the United States

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.
